NO20072906L - Metode for forhindring eller behandling av respiratoriske infeksjoner og akutt otitis media hos barn - Google Patents

Metode for forhindring eller behandling av respiratoriske infeksjoner og akutt otitis media hos barn

Info

Publication number
NO20072906L
NO20072906L NO20072906A NO20072906A NO20072906L NO 20072906 L NO20072906 L NO 20072906L NO 20072906 A NO20072906 A NO 20072906A NO 20072906 A NO20072906 A NO 20072906A NO 20072906 L NO20072906 L NO 20072906L
Authority
NO
Norway
Prior art keywords
children
otitis media
respiratory infections
preventing
acute otitis
Prior art date
Application number
NO20072906A
Other languages
English (en)
Other versions
NO341408B1 (no
Inventor
Erika Isolauri
Seppo Salminen
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of NO20072906L publication Critical patent/NO20072906L/no
Publication of NO341408B1 publication Critical patent/NO341408B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis

Abstract

Foreliggende oppfinnelse angår en ny metode for forhindring eller behandling av respiratoriske infeksjoner og akutt otitis media hos barn. Metoden omfatter administrering av en terapeutisk effektiv mengde av en Bifidobacteria-stamme og et adherens-fremmende probiotikum, så som LGG, til barnet.
NO20072906A 2004-07-01 2007-06-07 Forebygging eller behandling av respiratoriske infeksjoner og akutt otitis media hos barn. NO341408B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58483004P 2004-07-01 2004-07-01
PCT/US2005/023330 WO2006007526A1 (en) 2004-07-01 2005-07-01 Method for preventing or treating respiratory infections and acute otitis media in infants

Publications (2)

Publication Number Publication Date
NO20072906L true NO20072906L (no) 2007-06-07
NO341408B1 NO341408B1 (no) 2017-10-30

Family

ID=35058735

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072906A NO341408B1 (no) 2004-07-01 2007-06-07 Forebygging eller behandling av respiratoriske infeksjoner og akutt otitis media hos barn.

Country Status (13)

Country Link
US (1) US7862808B2 (no)
EP (1) EP1768681A1 (no)
KR (1) KR20070052246A (no)
CN (1) CN101014351B (no)
BR (1) BRPI0512584A (no)
CA (1) CA2570481C (no)
HK (1) HK1111883A1 (no)
MX (1) MXPA06014555A (no)
MY (1) MY145410A (no)
NO (1) NO341408B1 (no)
RU (1) RU2332224C1 (no)
TW (1) TWI374745B (no)
WO (1) WO2006007526A1 (no)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
DE602004006258T3 (de) * 2004-08-24 2013-08-29 Nutricia N.V. Nahrungszusammensetzung die unverdauliche Transgalaktooligosaccharide sowie verdauliche Galaktose-Saccharide enthält
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
EP1776877A1 (en) * 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
EP2035023A1 (en) * 2006-06-13 2009-03-18 Nestec S.A. Prevention and treatment of otitis media with non-pathogenic bacterial strains
PL2839836T3 (pl) 2006-10-02 2018-02-28 Dupont Nutrition Biosciences Aps Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego
EP1992351B1 (en) * 2007-05-18 2016-05-11 Nestec S.A. Lactobacillus johnsonii for prevention of postsurgical infection
WO2009021585A1 (en) * 2007-08-13 2009-02-19 Dsm Ip Assets B.V. Probiotic bacteria for rducing the occurence of symptoms of winter infections
EP2060257A1 (en) 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
CN102014673B (zh) * 2008-03-28 2014-07-30 雀巢产品技术援助有限公司 用于怀孕的雌性哺乳动物的以增强她们的后代的免疫性的益生菌剂
AR072141A1 (es) * 2008-06-13 2010-08-11 Nutricia Nv Composicion nutricional para lactantes nacidos por cesarea
WO2009151315A1 (en) * 2008-06-13 2009-12-17 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
WO2010002241A1 (en) * 2008-06-30 2010-01-07 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
EP2459202A1 (en) * 2009-07-31 2012-06-06 Nestec S.A. Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9408880B2 (en) 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
EP2335502A1 (en) * 2009-12-07 2011-06-22 Nestec S.A. An infant formula delivery system comprising probiotics and an infant nutritional formulation
WO2011093907A1 (en) * 2010-02-01 2011-08-04 Corn Products International, Inc. High-purity galactooligosaccharides and uses thereof
CN103220921B (zh) * 2010-10-15 2015-12-16 科.汉森有限公司 免疫佐剂
EP2455092A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2452575A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Array of age-tailored nutritional formula with probiotics
EP2452571A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Array of complementary infant/young child nutritional compositions
WO2012071380A1 (en) * 2010-11-24 2012-05-31 Oragenics, Inc. Use of bacteria to treat and prevent respiratory infections
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
MY187589A (en) 2011-06-20 2021-09-30 Heinz Co Brands H J Llc Probiotic compositions and methods
ES2795976T3 (es) * 2012-01-13 2020-11-25 Chr Hansen As Lactobacillus rhamnosus y Bifidobacterium animalis subsp. lactis para uso en la prevención o el tratamiento de infecciones de las vías respiratorias altas
CN108771687A (zh) 2012-02-29 2018-11-09 伊西康内外科公司 微生物区系的组合物及与其相关的方法
WO2013187755A1 (en) 2012-06-14 2013-12-19 N.V. Nutricia Fermented infant formula with non digestible oligosaccharides
WO2014178007A2 (en) * 2013-05-02 2014-11-06 Pinaki Panigrahi A pharmaceutical composition comprising a combination of probiotic and prebiotic
TR201908066T4 (tr) 2013-05-10 2019-06-21 Heinz Co Brands H J Llc Probiyotikler ve kullanım yöntemleri.
CN114468302A (zh) 2013-11-15 2022-05-13 雀巢产品有限公司 用于预防或治疗有风险婴儿或幼儿的urt感染的组合物
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
WO2015140299A1 (en) 2014-03-20 2015-09-24 Universiteit Antwerpen Oronasopharyngeal probiotics
FI127483B (en) * 2014-06-11 2018-07-13 Gut Guide Oy Microbial marker for celiac disease and related product
CN113730442A (zh) 2014-10-31 2021-12-03 潘德勒姆治疗公司 与病症的微生物治疗和诊断有关的方法和组合物
WO2018217764A1 (en) * 2017-05-22 2018-11-29 Kansas State University Research Foundation Microbiome transplantation
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
EP3517119B1 (en) 2018-01-26 2021-08-11 Probisearch, S.L.U. Composition comprising new lactobacillus salivarius strain and method for the prevention and treatment of otitis and upper respiratory infections
CN111184749B (zh) * 2020-02-17 2023-10-03 上海城建职业学院 一种益生菌菌剂、棉签及其制备方法和应用
US11602541B2 (en) 2020-04-24 2023-03-14 Joseph Scivoletto Nasal spray composition
WO2023118197A1 (en) * 2021-12-20 2023-06-29 Société des Produits Nestlé S.A. Secretory iga-biotic complexes and uses thereof
WO2023209224A1 (en) 2022-04-29 2023-11-02 Université Libre de Bruxelles Probiotics for the prevention or treatment of viral respiratory infections

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
JPS62138147A (ja) * 1985-12-12 1987-06-20 Snow Brand Milk Prod Co Ltd ガラクトオリゴ糖類配合飼料
US5840318A (en) * 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
JPH092959A (ja) 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
CA2281706C (en) 1997-02-21 2008-08-05 Abbott Laboratories Methods and compositions for reducing the incidence of necrotizing enterocolitis
CN1208620A (zh) * 1997-08-15 1999-02-24 陈秀枢 一种含双歧杆菌和乳杆菌的组合物
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
JP2002532420A (ja) 1998-12-15 2002-10-02 アメリカン・ホーム・プロダクツ・コーポレイション 腸管完全性の維持および回復のための方法および組成物
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
AU4905300A (en) * 1999-05-25 2000-12-12 Andrew W. Bruce Oral administration of lactobacillus for the maintenance of health in women
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
FI113741B (fi) 1999-11-01 2004-06-15 Valio Oy Menetelmä verenpainetta alentavia peptidejä sisältävän tuotteen valmistamiseksi
AU2001233529A1 (en) * 2000-02-10 2001-08-20 Andrew W. Bruce Probiotic therapy for newborns
AUPQ761200A0 (en) 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
EP1296693A4 (en) 2000-06-19 2005-05-25 Mucoprotec Pty Ltd IMMUNOTHERAPY AND PROBIOTIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL OR VIRAL INFECTIONS ON MUCOSAL SURFACES
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
JP2004531477A (ja) * 2001-02-06 2004-10-14 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 乳酸菌及びビフィズス菌による内毒素結合
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP3853673B2 (ja) 2001-03-09 2006-12-06 森永乳業株式会社 Ｃ型慢性肝炎治療剤
EP1243273A1 (en) * 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
EP1260227A1 (en) * 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
EP1596872B1 (en) 2003-01-24 2011-06-22 Flora Technology Inc. Compositions and methods for restoring bacterial flora
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
CN1183960C (zh) * 2003-02-27 2005-01-12 四川大学 双歧杆菌细胞壁蛋白在制药中的应用
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies

Also Published As

Publication number Publication date
CA2570481A1 (en) 2006-01-19
BRPI0512584A (pt) 2008-03-25
CA2570481C (en) 2014-09-09
EP1768681A1 (en) 2007-04-04
RU2332224C1 (ru) 2008-08-27
KR20070052246A (ko) 2007-05-21
CN101014351B (zh) 2011-08-24
MXPA06014555A (es) 2007-03-23
US20060018890A1 (en) 2006-01-26
HK1111883A1 (en) 2008-08-22
TWI374745B (en) 2012-10-21
MY145410A (en) 2012-02-15
WO2006007526A1 (en) 2006-01-19
TW200612971A (en) 2006-05-01
US7862808B2 (en) 2011-01-04
CN101014351A (zh) 2007-08-08
NO341408B1 (no) 2017-10-30

Similar Documents

Publication Publication Date Title
NO20072906L (no) Metode for forhindring eller behandling av respiratoriske infeksjoner og akutt otitis media hos barn
DK1721612T3 (da) Immunmodulerende oligosaccharider
CY1112560T1 (el) Πνευμονικη μεταφορα των αμινογλυκοσιδων
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
WO2010036945A3 (en) Nanoemulsion therapeutic compositions and methods of using the same
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
TR200200065T2 (tr) Dış salgılama bozukluklarının tedavisi için terkip
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
SI1878738T1 (sl) 1-kestoza za zdravljenje alergije in atopiäśnega dermatitisa
WO2002047668A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und ciclesonide
TNSN08284A1 (en) Masking the taste of powders
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
WO2005112915A3 (en) Decrease in oxidative stress status through the administration of natural products and pharmaceutical drugs
WO2005018605A3 (en) Novel formulation of ropinirole
MX2009003260A (es) Probioticos para el uso en la reduccion de la incidencia y duracion de la enfermedad.
NO20076405L (no) Anvendelse av 24-nor-UDCA
ATE455789T1 (de) Substituierte nonadepsipeptide
CY1109668T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει βακιλλο bacillus coagulans και σιμεθικονη για τη θεραπεια γαστρεντερικων παθολογιων
HRP20050580B1 (hr) Sinergistiäśki uäśinak kombinacije roflumilasta i (r,r)-formoterola
ATE478680T1 (de) Verhinderung von allergie bei kindern
NO20074767L (no) Anvendelse av rimonabant for fremstilling av medikamenter som kan anvendes i forebygging og behandling av type 2 diabetes
UA92908C2 (ru) Соединения, производные от 5-тиоксилозы, и их терапевтическое применение
BRPI0511945A (pt) mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia
WO2003053959A8 (de) Heterocyclylaminocarbo nyluracile
TW200635580A (en) Methods of treatment and prevention

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MJN U.S. HOLDINGS LLC, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MJN U.S. HOLDINGS LLC, US

MM1K Lapsed by not paying the annual fees